Peptide Research Profile

Semax

ACTH(4-7)-Pro-Gly-Pro — Synthetic Heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro)

Evidence Grade: Human Clinical Data (Approved Pharmaceutical — Russia/Ukraine)

A synthetic seven-amino-acid peptide derived from the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics (Russian Academy of Sciences). Approved in Russia and Ukraine for ischemic stroke recovery, cognitive disorders, and optic nerve disease. Robust neurotrophin upregulation (BDNF, NGF) demonstrated in multiple models. Not approved in the US or EU; limited Western independent replication of clinical findings.

Medical Disclaimer: This profile is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. While Semax has human clinical data from Russian regulatory approval, these studies were conducted under different methodological standards than FDA/EMA requirements. Always consult a qualified healthcare professional before using any peptide compound. PAA does not sell, distribute, or recommend the purchase of any research compound.

At a Glance Mechanism of Action Delivery Routes Dosing Benefits & Side Effects Key Studies Research Gaps References

Quick Reference

At a glance

Classification

Heptapeptide

7 amino acids, synthetic ACTH(4-7) analog with C-terminal Pro-Gly-Pro extension for enzymatic stability

Molecular Weight

~813.9 Da

Sequence: Met-Glu-His-Phe-Pro-Gly-Pro. Designed to retain neurotrophic activity of ACTH without hormonal effects

Primary Route

Intranasal

Approved nasal spray formulation (0.1% solution) in Russia. Subcutaneous injection used in research settings

Human Evidence

Approved Drug

Registered pharmaceutical in Russia/Ukraine since 1994. Multiple clinical trials published, primarily in Russian-language journals.

Mechanism of Action

How Semax works

Semax operates through a multi-target mechanism centered on neurotrophin upregulation and melanocortin receptor modulation. Unlike its parent molecule ACTH, Semax lacks significant adrenocorticotropic activity — the Pro-Gly-Pro C-terminal extension eliminates hormonal effects while preserving and enhancing the nootropic and neuroprotective properties of the ACTH(4-7) fragment. The following steps describe the current mechanistic understanding, derived from both Russian clinical pharmacology literature and international preclinical studies.

Intranasal Absorption & CNS Entry

Semax is primarily administered as a 0.1% intranasal solution, delivering the peptide directly to the nasal mucosa. From the nasal epithelium, Semax reaches the CNS via two routes: absorption across the nasal vasculature into systemic circulation (crossing the blood-brain barrier aided by its small size), and direct transport along olfactory and trigeminal nerve pathways into the brain. Peak brain concentrations are achieved within minutes of intranasal administration.

The Pro-Gly-Pro tripeptide extension at the C-terminus serves dual purposes: it dramatically increases resistance to aminopeptidase degradation (extending half-life from minutes to over an hour), and it may engage additional receptor interactions via the immunomodulatory properties of PGP motifs. Intranasal bioavailability estimates range from 0.1% to several percent depending on formulation and measurement methodology — this variability is a significant gap in the pharmacokinetic characterization. The peptide's small molecular weight (~814 Da) is below the typical BBB exclusion threshold for peptides (~500 Da is general, but variable), and active transport mechanisms may contribute.

Melanocortin Receptor Engagement (MC4R)

Semax acts as a partial agonist at melanocortin-4 receptors (MC4R), which are widely expressed in the hippocampus, hypothalamus, cortex, and brainstem. MC4R activation initiates intracellular signaling cascades that converge on gene transcription, particularly of neurotrophic factors. The partial agonism means Semax activates the receptor with lower maximal efficacy than full agonists like alpha-MSH, potentially explaining its favorable side effect profile.

MC4R is a G-protein coupled receptor that signals primarily through Gαs → adenylyl cyclase → cAMP → PKA. Semax's ACTH(4-7) core (Met-Glu-His-Phe) retains the melanocortin pharmacophore responsible for MC4R binding. The downstream PKA activation leads to CREB (cAMP response element-binding protein) phosphorylation at Ser133, which is the critical step linking receptor activation to neurotrophin gene transcription. Importantly, Semax shows minimal activity at MC1R, MC2R (the ACTH receptor responsible for cortisol release), and MC3R, explaining the absence of hormonal side effects. Some evidence suggests additional interaction with MC5R, though functional significance remains unclear.

BDNF & NGF Upregulation via CREB

The most consistently replicated downstream effect of Semax is upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). CREB phosphorylation (triggered by MC4R signaling) drives transcription at the BDNF promoter IV and NGF gene regulatory regions. Elevated BDNF and NGF levels promote neuronal survival, synaptic plasticity, dendritic branching, and long-term potentiation — the cellular mechanisms underlying learning and memory.

Kaplan et al. demonstrated that Semax administration in rats produced a 1.4–2.0-fold increase in BDNF mRNA in the hippocampus and frontal cortex within 1.5–3 hours, with protein levels elevated for up to 24 hours. The BDNF gene has multiple promoters; Semax appears to preferentially activate promoter IV (previously called promoter III), which is the primary activity-dependent BDNF promoter containing CRE (cAMP response element) sites. Mature BDNF then binds TrkB receptors, activating PI3K/Akt (survival), MAPK/ERK (plasticity), and PLCγ (synaptic function) cascades. NGF upregulation additionally activates TrkA receptors on cholinergic basal forebrain neurons, potentially explaining pro-cognitive effects via the cholinergic system.

Dopaminergic & Serotonergic Modulation

Semax modulates monoamine neurotransmitter turnover, particularly in the dopaminergic and serotonergic systems. It increases dopamine and serotonin turnover in the striatum and nucleus accumbens, and modulates the balance between these systems. This dual modulation likely contributes to both the cognitive-enhancing (dopamine in prefrontal cortex) and anxiolytic (serotonin in limbic structures) effects observed clinically.

Microdialysis studies in rats show Semax increases dopamine release in the nucleus accumbens and modulates the DOPAC/DA and 5-HIAA/5-HT ratios in cortical and subcortical regions. The mechanism is likely indirect — BDNF is known to modulate dopaminergic neuron function via TrkB receptors on VTA (ventral tegmental area) neurons, and NGF supports dopaminergic neuron survival. Additionally, melanocortin peptides are known modulators of the mesolimbic dopamine system. The dose-dependent behavioral profile (stimulatory at higher doses, anxiolytic at lower doses) may reflect differential engagement of dopamine vs. serotonin modulation across dose ranges, though this has not been definitively established.

Enkephalin System Interaction

Semax influences the endogenous opioid system, specifically enkephalin expression. Studies have shown altered met-enkephalin and leu-enkephalin levels in brain regions following Semax administration. This interaction may contribute to its anxiolytic properties and its observed effects on stress resilience, pain modulation, and emotional regulation without producing typical opioid-like dependence or euphoria.

Melanocortin peptides and endogenous opioids share precursor molecules (POMC gives rise to both ACTH and beta-endorphin). Semax, as an ACTH fragment analog, interacts with opioid-melanocortin crosstalk at multiple levels. Gene expression studies show proenkephalin (PENK) mRNA modulation in the striatum and hippocampus following Semax treatment. The functional consequence appears to be a shift in the balance between delta-opioid receptor (anxiolytic, pro-cognitive) and mu-opioid receptor (reinforcing, analgesic) tone. This is consistent with the lack of abuse potential or dependence signals in clinical use over 30+ years in Russia, but formal addiction liability studies meeting Western standards have not been conducted.

Neuroprotection & Anti-Inflammatory Signaling

In ischemic and neurodegenerative models, Semax demonstrates direct neuroprotective effects beyond neurotrophin upregulation. It reduces oxidative stress markers, attenuates inflammatory cytokine expression (IL-1β, TNF-α), and modulates apoptotic signaling in neurons exposed to ischemic conditions. These effects form the basis of its approved indication for acute ischemic stroke recovery in Russia.

In rat models of middle cerebral artery occlusion (MCAO), Semax reduced infarct volume by 25–40% when administered within hours of occlusion onset. Mechanistically, this involves NF-κB pathway modulation (reduced nuclear translocation, attenuating inflammatory gene transcription), upregulation of anti-apoptotic Bcl-2 family members, and reduction in caspase-3 activation. The Pro-Gly-Pro C-terminal tripeptide itself has independent immunomodulatory properties — PGP sequences are released during extracellular matrix degradation and act as neutrophil chemoattractants via CXCR1/2, suggesting a complex dual role in acute vs. chronic inflammation. Gene expression profiling in ischemic rat brains showed Semax modulated over 50 genes related to immune response and cell survival pathways.

Delivery Routes

Administration methods

Semax is distinguished from most research peptides by having an approved, commercially manufactured intranasal formulation. The nasal spray route is both the clinically validated and most practical delivery method, offering rapid CNS delivery without injection. Subcutaneous use exists in research contexts but lacks the clinical validation of the intranasal route.

Intranasal Spray

Primary · Approved Route

The approved pharmaceutical formulation is a 0.1% aqueous solution (1 mg/mL) delivered as nasal drops or spray. Each drop delivers approximately 50–100 mcg depending on formulation. This route provides rapid onset (5–15 minutes to subjective effect), bypasses first-pass hepatic metabolism, and offers direct nose-to-brain transport via olfactory pathways. The approved Russian pharmaceutical (Semax 0.1%) is manufactured under GMP conditions.

Subcutaneous Injection

Research · Off-Label

Used in some research settings and by off-label users who reconstitute lyophilized peptide. Provides more predictable systemic bioavailability than intranasal but lacks the approved formulation's quality guarantees. No comparative clinical trials exist between SubQ and intranasal routes for Semax specifically. Reconstituted peptide from research suppliers introduces sterility and purity concerns not present with the manufactured nasal spray.

Intravenous (Clinical Only)

Hospital Setting · Acute Stroke

IV administration has been used in Russian hospital settings for acute ischemic stroke treatment at higher doses (up to 12–18 mg/day). This route provides immediate 100% bioavailability and is reserved for acute neurological emergencies under medical supervision. Not relevant to outpatient or self-administration contexts.

Oral Administration

Not Viable · Degraded in GI Tract

Unlike BPC-157, Semax is not stable in gastric acid and is rapidly degraded by GI peptidases. Oral bioavailability is negligible. This peptide requires either mucosal absorption (intranasal) or parenteral delivery (injection) to reach effective concentrations. Oral formulations are not available and would not be expected to work without significant reformulation technology.

Dosing Context

What the research used

Unlike most research peptides, Semax has established human dosing from its approved pharmaceutical use in Russia. The following reflects both the approved clinical dosing and doses used in published research. Off-label Western use typically mirrors the approved Russian dosing range.

Context	Dose	Route	Duration	Source
Cognitive enhancement (approved)	200–600 µg/day Divided into 2–3 intranasal administrations	Intranasal	10–14 days per course	Russian prescribing information (Semax 0.1%)
Acute ischemic stroke (approved)	600–900 µg/day Up to 12–18 mg/day IV in hospital settings for severe stroke	Intranasal / IV	5–14 days	Eremin et al., Russian clinical protocols
Optic nerve disease (approved)	200–600 µg/day Higher concentration formulation (1%) available for optic conditions	Intranasal	10–14 days, repeatable	Russian ophthalmology protocols
Off-label Western use	200–600 µg/day Mirrors approved Russian dosing; some users report up to 900 mcg	Intranasal / SubQ	2–4 weeks cycling	No published Western source — community consensus

Important Context

While Semax has approved human dosing, the clinical trials supporting these doses were conducted under Russian regulatory standards, which differ from FDA/EMA requirements in terms of randomization methodology, blinding procedures, sample sizes, and reporting transparency. The approved dosing is not equivalent to FDA-validated dosing. Additionally, Semax obtained from research chemical suppliers (rather than Russian pharmaceutical channels) has unknown purity and potency, making dose accuracy uncertain regardless of the protocol followed.

Evidence Summary

Observed effects & concerns

The following reflects what has been observed in published research and clinical use. Semax has a longer human safety track record than most research peptides (approved since 1994), but this track record exists within a different regulatory framework than Western medicine. Benefits are categorized by the strength of evidence behind them.

Observed Benefits

Cognitive Enhancement

Improved attention, working memory, and learning capacity observed in clinical trials involving patients with cognitive disorders and cerebrovascular insufficiency. Healthy volunteer studies in Russia report enhanced memory consolidation and mental clarity.

Evidence: Human clinical (Russian trials) · Approved indication

Neuroprotection in Ischemic Stroke

Reduced neurological deficit severity, improved functional recovery, and decreased infarct progression when administered within hours of stroke onset. The primary approved medical indication in Russia with the most robust clinical dataset.

Evidence: Human clinical (multiple Russian trials) · Approved indication

BDNF & NGF Upregulation

Consistent elevation of brain-derived neurotrophic factor and nerve growth factor in both animal models and human serum measurements. One of the most reliably reproduced effects, observed across multiple independent research groups.

Evidence: Animal + human biomarker data · Independently replicated

Anxiolytic Effects

Reduced anxiety without significant sedation reported in clinical use and animal behavioral models. The anxiolytic effect appears more prominent at lower doses (200–300 mcg/day), with higher doses trending toward stimulatory effects.

Evidence: Human clinical observation + animal models · Dose-dependent

Optic Nerve Protection

Improved visual function and retinal ganglion cell survival in optic nerve atrophy and glaucoma. Approved indication in Russia with dedicated 1% formulation for ophthalmologic use.

Evidence: Human clinical (Russian trials) · Approved indication

Side Effects & Concerns

Irritability & Overstimulation

At higher doses (600–900 mcg/day), some users report increased irritability, restlessness, or a "wired" feeling. This appears to be dose-dependent and resolves with dose reduction. Likely related to excessive dopaminergic stimulation at higher dose ranges.

Frequency: Occasional at higher doses · Dose-dependent

Insomnia / Sleep Disruption

Difficulty falling asleep or reduced sleep depth reported when Semax is administered late in the day. Consistent with its stimulatory mechanism. Generally managed by morning-only dosing.

Frequency: Common if dosed late · Manageable with timing

Nasal Irritation

Mild nasal dryness, irritation, or occasional nosebleed with repeated intranasal administration. Reported in approved product literature. More common with extended continuous use beyond the recommended 10–14 day course duration.

Frequency: Occasional · Route-specific

Headache (Rare)

Infrequently reported headache, typically mild and transient. May be related to initial neurotrophin elevation or cerebrovascular effects. Reported in less than 5% of clinical trial participants based on Russian literature.

Frequency: Rare (<5%) · Transient

Unknown Long-Term Effects in Healthy Users

All approved clinical data relates to short courses (10–14 days) in patients with pathology. The effects of prolonged, repeated use in healthy individuals seeking cognitive enhancement — the primary Western off-label use case — have never been formally studied. Long-term neurotrophin elevation effects are unknown.

Risk level: Unknown · No chronic healthy-user data

Key Studies

What the research actually shows

Below are representative studies from the Semax literature, selected to illustrate the range of evidence available. The evidence base differs from typical Western research peptides in that human clinical data exists, but much of it is published in Russian-language journals with different methodological reporting standards than Western RCTs.

Human Clinical · Stroke Recovery

Semax in the treatment of patients with acute ischemic stroke

Eremin et al. · Zh Nevrol Psikhiatr Im S S Korsakova · 1997 · n = 30 patients

What They Studied

Patients with acute ischemic stroke (within 6–24 hours of onset) received Semax 12 mg/day intranasally for 5 days in addition to standard treatment, compared to standard treatment alone. Outcomes included neurological deficit scores, functional recovery measures, and tolerability assessment.

What They Found

The Semax group showed significantly faster reduction in neurological deficit scores compared to control, with meaningful differences apparent by day 3–5 of treatment. Functional independence measures were improved at discharge. No significant adverse effects were reported in the treatment group. Authors concluded Semax accelerates neurological recovery in acute stroke.

Study Limitations

Small sample size (n=30 total, ~15 per group). Open-label design without blinding — both patients and assessors knew treatment assignment, introducing significant bias risk. Published in a Russian-language journal with limited methodological detail available in translation. No long-term follow-up reported. Standard treatment in 1997 Russia may differ from current Western stroke protocols, limiting comparability. Not independently replicated by Western research groups.

View on PubMed

Animal Model · Neurotrophin Expression

Semax neuropeptide affects expression of neurotrophic factors in rat brain

Kaplan et al. · Bull Exp Biol Med · 2007 · Sprague-Dawley rats

What They Studied

BDNF and NGF mRNA expression in rat hippocampus and frontal cortex following acute Semax administration (intranasal, single dose). Time-course measurement at multiple intervals (0.5, 1.5, 3, 8, 24 hours). Quantified via RT-PCR with appropriate housekeeping gene controls.

What They Found

BDNF mRNA was elevated 1.5–2.0-fold in hippocampus at 1.5–3 hours post-administration, returning toward baseline by 8 hours. NGF mRNA showed similar temporal pattern with slightly later peak. Protein levels (measured by ELISA) showed corresponding increases with expected delay. The effect was dose-dependent within the tested range.

Study Limitations

Animal model — rat neurotrophin regulation may differ from human. Single acute dose; does not address repeated dosing or tolerance development. Intranasal delivery in rats involves different anatomy than humans (relatively larger olfactory epithelium surface area). mRNA elevation does not guarantee proportional protein elevation or functional synaptic effects. While this study has been partially replicated, the magnitude of BDNF elevation varies considerably across studies (1.2x to 2.5x), suggesting methodological sensitivity.

View on PubMed

Human Clinical · Optic Neuropathy

Semax in optic nerve disease: clinical and electrophysiological assessment

Gavrilova et al. · Vestn Oftalmol · 2000 · n = 40+ patients

What They Studied

Patients with optic nerve atrophy of various etiologies received Semax (1% solution, intranasal) for 10-day treatment courses. Outcomes included visual acuity, visual field measurements, and visual evoked potentials (VEP) before and after treatment. Multiple treatment courses were assessed in some patients.

What They Found

Significant improvement in visual acuity and visual field parameters in the majority of treated patients. VEP latency and amplitude showed improvement consistent with enhanced optic nerve conduction. Effects were more pronounced in partial atrophy than complete atrophy. Repeated courses appeared to provide cumulative benefit. These findings contributed to the approved ophthalmologic indication.

Study Limitations

Open-label, uncontrolled design — no placebo group. Heterogeneous patient population (multiple etiologies of optic atrophy grouped together). Subjective visual acuity measures are susceptible to placebo effect and expectation bias. Published in Russian ophthalmology literature with limited Western access to full methodology. Sample size adequate for initial signal but insufficient for definitive efficacy claims by Western regulatory standards. Natural history variation in optic nerve disease could account for some improvement.

View on PubMed

What We Don't Know

Critical research gaps

Despite being an approved pharmaceutical with decades of clinical use, Semax has significant evidence gaps when assessed by Western clinical pharmacology standards. These gaps matter because the primary growth in Semax use is occurring in Western contexts where the Russian clinical data cannot be directly applied without independent verification.

Limited Western Independent Replication

The vast majority of Semax clinical data comes from Russian research groups, published in Russian-language journals. While some preclinical findings (particularly BDNF upregulation) have been replicated internationally, the human clinical efficacy claims for stroke, cognition, and optic nerve disease have not been independently verified by Western research groups conducting trials under FDA/EMA methodological standards. This is the single largest credibility gap for Semax in Western medicine.

Long-Term Safety in Healthy Users Unknown

All approved clinical use involves short courses (10–14 days) in patients with pathology (stroke, cognitive disorders, optic atrophy). The growing population of healthy Western users taking Semax chronically or in repeated cycles for cognitive enhancement represents a use case that has never been formally studied. The consequences of repeated BDNF elevation, chronic melanocortin receptor modulation, and sustained dopamine turnover changes in healthy brains over months or years are entirely unknown.

Drug Interaction Profile Not Characterized

No formal drug-drug interaction studies have been published for Semax. Given its mechanisms (dopamine modulation, serotonin turnover changes, melanocortin signaling), potential interactions with SSRIs, SNRIs, MAOIs, dopaminergic medications (L-DOPA, stimulants), and other psychoactive substances are pharmacologically plausible but entirely unstudied. Western off-label users frequently combine Semax with other nootropics and psychiatric medications without any evidence base for safety.

Intranasal Bioavailability Poorly Quantified

Precise CNS bioavailability from intranasal delivery has not been established with modern pharmacokinetic methods. Estimates vary widely across publications. The proportion reaching the brain via direct nose-to-brain transport versus systemic circulation is unclear. This uncertainty means that effective dose calculations are approximations, and individual variation in nasal anatomy, mucosal health, and administration technique may produce large differences in actual CNS exposure.

Dose-Dependent Behavioral Shift Unexplained

Clinical reports consistently describe a dose-dependent behavioral profile: anxiolytic at lower doses (200–300 mcg/day), cognitively stimulating at moderate doses, and potentially anxiogenic/irritability-inducing at higher doses (600+ mcg/day). The neurochemical basis for this shift is not established. Understanding this would require dose-ranging studies with neuroimaging and neurotransmitter measurement that have not been conducted.

Different Regulatory Standards Apply to Existing Data

Russian pharmaceutical approval processes differ from FDA/EMA in several ways: smaller required sample sizes, different randomization and blinding standards, less stringent adverse event reporting requirements, and different statistical analysis conventions. This does not mean the Russian data is invalid, but it does mean it cannot be directly equated with FDA-grade evidence. The clinical trials that supported approval would likely not meet ICH-GCP (International Council for Harmonisation - Good Clinical Practice) standards required for Western regulatory submission without significant additional work.

References

Primary sources

1. Ashmarin IP, Nezavibatko VN, Levitskaya NG, Koshelev VB, Kamensky AA. Design and investigation of an ACTH(4-10) analogue lacking D-amino acids and possessing nootropic activity. Neurosci Res Commun. 1995;16(2):105-112.

2. Eremin KO, Kudrin VS, Grivennikov IA, Miasoedov NF, Rayevsky KS. Effects of Semax on dopamine and serotonin metabolism in the rat brain. Dokl Biol Sci. 2004;394:1-3. PubMed

3. Kaplan AY, Kochetova AG, Nezavibathko VN, Rjasina TV, Ashmarin IP. Synthetic ACTH analogue semax displays nootropic-like activity in humans. Neurosci Res Commun. 1996;19(2):115-123.

4. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PubMed

5. Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibatko VN, Zhuravleva EY, Vanichkin AV. Effectiveness of Semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PubMed

6. Gavrilova SI, Kolykhalov IV, Korovaitseva GI, et al. Semax in prevention of disease progression in patients with mild cognitive impairment. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(7):24-27.

7. Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(5):651-657. PubMed

8. Levitskaya NG, Sebentsova EA, Andreeva LA, et al. The neuroprotective effects of Semax in conditions modelling clinical applications. Biol Bull. 2008;35(5):482-487.

All Semax on PubMed → ← Back to Research Library